INTERNAL POSITION MEMO

Sporos Government Affairs | Medicare Drug Price Negotiation *For internal review only — not legal advice. Grounded in cited records; see sourcing notes.*

Subject & Bottom Line

The Medicare Drug Price Negotiation Program, established under the Inflation Reduction Act (IRA), is in active multi-cycle implementation by CMS. The program sets a Maximum Fair Price (MFP) on selected drugs for Medicare beneficiaries and is generating sustained legislative, regulatory, and legal activity. The program is not static: CMS is now running a third negotiation cycle, initiating the first renegotiation cycle, and extending MFP effectuation through 2028 ^[6]. Concurrently, Congress is legislating at the margins — both to narrow the program's scope (e.g., orphan drug carve-outs ^[1]) and to protect or expand its consumer-facing effects ^[3][5]. Any principal with a stake in pharmaceutical pricing, Medicare plan design, or drug innovation policy faces a materially changed landscape and should develop a durable, cycle-aware engagement strategy.

Background

The IRA's Medicare negotiation authority has moved from enactment into operational reality. CMS published draft guidance for the third negotiation cycle and first renegotiation cycle in May 2025 ^[7], accepted public comment, and finalized that guidance on November 28, 2025 ^[6]. The finalized guidance governs MFP effectuation in 2026, 2027, and 2028 — meaning manufacturers of selected drugs are now operating under binding price ceilings for the medium term. A second-cycle final guidance was published in October 2024, covering MFP effectuation in 2026–2027 ^[10]. The program is therefore running on overlapping cycles, with negotiation, renegotiation, and effectuation timelines layered simultaneously.

Alongside CMS implementation, Congress has been active. Bills introduced in the 119th Congress (2025–present) address specific structural features of the program: S. 3019 targets the orphan drug exemption ^[1]; H.R. 5094 and H.R. 3731 address patient cost and small biotech treatment, respectively ^[2][5]; S. 2447 engages pricing-adjacent issues ^[3]. The constitutional and APA litigation landscape remains a live variable, with CRS having produced multiple analyses of legal challenges ^[11][12][13].

What the Record Shows

1. CMS has finalized third-cycle and first renegotiation guidance (November 2025). The November 28, 2025 Federal Register notice ^[6] announces final guidance for the third negotiation cycle, the first-ever renegotiation cycle, and MFP effectuation extending through 2028. This is the most operationally significant record in the set: it means the program is deepening (more drugs, longer price-ceiling horizons) rather than contracting. Any manufacturer or plan sponsor whose drug portfolio or formulary design intersects with the MFP list faces binding price constraints through at least 2028.

2. The orphan drug exemption is under direct legislative attack. S. 3019, introduced October 21, 2025 by Senators Welch, Wyden, and Cortez Masto ^[1], amends 42 U.S.C. § 1320f–1(e) — the section of the Social Security Act governing orphan drug treatment under the Negotiation Program. The bill's title ("No Big Blockbuster Bailouts Act") and its specific amendment strike a subparagraph of paragraph (1) and restructure paragraph (3), effectively narrowing the conditions under which a drug can claim orphan-drug exemption from negotiation. The practical implication: drugs that obtained orphan designation but achieved blockbuster commercial scale could lose their negotiation exemption. This is a significant structural change if enacted and should be monitored for Finance Committee movement.

3. The rulemaking record for Medicare Advantage and Part D has been finalized. The April 15, 2025 final rule ^[8] covers Contract Year 2026 policy changes to Medicare Advantage, the Part D drug benefit, and related programs (42 CFR Parts 417, 422, 423, et al.), running 130 Federal Register pages. This rule interacts with MFP implementation because Part D plan sponsors must incorporate negotiated prices into their formularies and bids. The proposed version was published December 10, 2024 ^[9]. Together, these records confirm that the MA/Part D regulatory architecture is being updated in parallel with negotiation cycles — plan sponsors face compounding compliance obligations.

4. Legal challenges are a documented, ongoing variable. Three CRS analyses specifically address litigation against the negotiation program: an APA-challenges report from November 2024 ^[11], a constitutional-challenges report from October 2024 ^[12], and an earlier APA implementation analysis from January 2024 ^[13]. The existence of multiple, updated CRS analyses signals that legal challenges have been substantive enough to warrant sustained congressional and policy attention. Note: The body text of these CRS reports was not extracted; the full scope of their legal analysis — including which cases were pending and their status — requires direct verification at EveryCRSReport.com or CRS directly. [BODY NOT EXTRACTED — flag for verification]

5. Small biotech and patient-protection legislation signals bipartisan structural pressure. H.R. 3731 (Small Biotech Innovation Act, June 4, 2025) ^[5] and H.R. 5094 (Protect Patients from Costly Care Act, September 2, 2025) ^[2] indicate that legislators on multiple sides are attempting to carve out, condition, or extend the program's effects — the former likely seeking preferential treatment for smaller innovators, the latter addressing patient-side cost exposure. Neither bill's full text was extracted; their committee referrals and floor prospects require verification. [BODY NOT EXTRACTED — flag for verification]

Stakeholder Landscape

CMS / HHS (Executive): The primary implementing actor. CMS has run the program through two completed cycles and is now executing a third cycle plus first renegotiation, with guidance finalized through 2028 ^[6][7][10]. Under the current administration, implementation appears to be continuing rather than being dismantled.

Congressional Democrats (pro-negotiation, pro-expansion): Senators Welch, Wyden, and Cortez Masto are actively legislating to close what they characterize as an "orphan drug loophole" exploited by blockbuster drugs ^[1]. S. 2447 ("Repealing the Trump Sick Tax Act") suggests continued Democratic effort to protect or extend IRA pricing provisions ^[3].

Congressional Republicans / Industry-aligned members: H.R. 3731 (Small Biotech Innovation Act) ^[5] suggests at least some members are seeking to limit the program's reach for specific innovator categories. H.R. 1 (FEHB Protection Act of 2025) ^[4] — the bill text was not extracted; its relationship to drug pricing requires docket confirmation before any inference is drawn. [NAME-MATCH; flag for verification]

Pharmaceutical Manufacturers: The lobbying records in the set are dated Q1 2020 ^[16][17][18] — these are five-year-old filings and cannot be treated as current lobbying activity. Bristol-Myers Squibb ($540K, Q1 2020) ^[16], Boehringer Ingelheim ($925K, Q1 2020) ^[17], and Takeda ($940K, Q1 2020) ^[18] appear in the record, but their current positions and spending on this specific issue require fresh LDA database queries. Do not rely on these records for current stakeholder mapping.

Patient/Consumer Advocates: The Alliance for Retired Americans reported $70K in Q1 2020 lobbying ^[19] — again, stale. Presumptively supportive of negotiation based on organizational mission, but current engagement level is unverified from this record set.

Insurers/Plans: Blue Cross Blue Shield of Kansas appeared in a Q1 2020 LDA record ^[20] — stale; dollar amount not reported in the excerpt. Plan sponsors broadly have a structural interest in MFP incorporation into Part D bids and formularies, but current positions require fresh research.

Recommended Position & Rationale

*The following is advocacy/recommendation, not sourced fact.*

Recommended position: Engage the third-cycle and renegotiation guidance as a priority, monitor S. 3019 closely, and build a comment/coalition strategy around renegotiation methodology.

Rationale:

• The finalization of third-cycle and renegotiation guidance ^[6] is the hinge event. Renegotiation is new procedural territory — CMS is writing its methodology in real time, and the comment record from the draft phase ^[7] is where principal positions can be most efficiently placed on the docket. If the principal missed the draft comment window, the renegotiation framework should be a focus for the next cycle.
• S. 3019's orphan drug amendment ^[1] is a high-leverage, low-profile bill that could materially alter exemption eligibility for drugs with dual rare-disease/large-population indications. If the principal's portfolio includes any orphan-designated drugs with substantial Medicare volume, this bill warrants direct Finance Committee engagement now, before markup.
• The legal challenge landscape ^[11][12][13] — though not fully readable from extracted text — has been active enough to warrant a standing legal-monitor function. Any adverse ruling on APA or constitutional grounds could suspend or restructure MFP timelines, creating both risk and opportunity.
• The lobbying data in this record set is too old to be actionable for coalition mapping ^{[16][17][18][19][20]}. Recommended action: Pull current LDA filings (2024–2025) for the principal's peer manufacturers and patient organizations to map the current influence landscape before taking public positions.

Risks & Watch Items

*Grounded solely in records ^[1]–^[20] as cited above (capped sample); prepared for internal review; not legal